الجمعة، 13 يناير 2012

Abimol

Indication:
Analgesic and antipyretic, and is recommended for the treatment of most painful and febrile conditions, for  example, headache including migraine and tension headaches, toothache.. backache, rheumatic and muSele Pah% dInMetleffth0a0, sore throat, and Sot reeving the fever, aches and pains of colds and flu. Also recommender/lot the symptomatic relief of pain due to non-serious aWnntis.
00,1Qe Br Administration:
Adults:
One to two tablets every 4 to 6 hours up to tour times daily as required. Maximum daily dose is 4000 mg. On not exceed the slated dose. banal take more than 8 tablets in 24 hours. Do not take more frequently than every four hours
Children: Children should not be given Abonol fOr more than 3 days without consulting a doctor. No more than 4 doses to be taken in any 24 hour period The maximum daily dose is 6Orng/kg
6 - 12 years: Half to one tablet three or four times daily as required.
1 - 6 years: 5 to 10 Int of the liquid suspension (120 to 240 mg of paracetamol). Dose may he repeated after 4 hours.
3 months to less than 1 year: 2.5 to 5 ml of tht liquid suspension (60 to 120 mg of paracetamol). Dose may be repeated
after 4 hours.
Less than) months; 2.5m1 of the liquid suspension may be administered to infants who devtlop pyrexia after vaccination at
2 months Al age. If necessary, a second dose can be given 4-6 hours later. If uremia persists after the second dose, medical attention is required.
For all other indicatiOns in this age group, use only under medical supervision.
Abimol should not be used with Other paracetamol containing products.
Contra-Indications:
Abimol is contraindicated in patients with a previous history Al hypersensitivity to paracetamol or exeipients.
Side Effects:
Paracetamol has been widely used and, when taken at the usual recommended dosage, ode effects are mild and infrequent and reports of adverse reactions are rare.
Skin rash and other allergic reactions, such as angioedema occur rarely.
In patients sensitive to aspinn or other NSAIDs. aggravation of bronchospastn has been reported.
Most reports of adverse Tactions to paracetamol relate to overdose with the drug
Isolated cases of blood dyscrasia, thromboeytopenic purputa. haemolytic anaemia and agranulocytosrs have been recorded. Chronic hepatic necrosis has been reported in a patient who look daily therapeutic doses of paracetamol for about a year and liver damage has been reported after daily ingestion of excessive amounts for shorter periods. A feN4CW of a group of patients with chronic active aepatitiS faded to reveal differences in the abnormalities of liver function in those who were long-term users of paracetamol nor was the control of their disease improved after paracetamol withdrawal.
11111111
Nephrotoxic effects Maoism therapeutic doses of paracetamol are uncommon. Papillary necrosis nas ban reported alter prolonged administration
Over dose & tre Olsen
Potentially fatal nerd age is litchi in adults who have taken 15g or more of paracetamol. As little as lOg may lead 10 liver necrosis Patients taking enzyme-inducing drugs of with a history of alcoholism may have an increased susceptibility. Ills considered that xcess q antities of a toxic metabolite (usually adequately detoxified by glutathione amen normal doses of paracetamol are mployed), become irreversibly bound to liver tissue.
Symptoms of paracetarn I over dosage in the first 24 hours are pallor, nausea, vomiting, diarrhoea. anorexia, abdominal pain and increased sweating, liver damage may become apparent 12 10 46 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, hepatic failure may progress to encephalopa thy, coma, and death. Acute renal failure with acute tubular necrosis may develop even in the absence of severe liver damage. Cardiac arrhythmia, have been reported.
Prompt treatment is essential in the management of paracetamol ovetdosage. Any patient who has ingested abcmt 2.5g or more of paracetamol in the preceding 4 hours should undergo gastric lavagc or induced ernesis. Specific therapy with an antidote such as acetyleyst err or methioninc may be necessary. Actrykysteine may be given either intravenoody of by mouth or methionine may be given by mouth within 10 -12 hours of ingestion of the overdose. Generally treatment is required if the blood-paracetamol concentration is higher than a line (the '200' line) drawn on semi‑
log/linear paper joining the points 200 mg/litre (1.32 mmofflitre) at 4 IMMS and 30 mg/litre (0.20 rnmolflitre) 01 15 henna following Ingestion
Determination of the concentration before 4 hours is not considered to give a reliable measurement. Administration of oral methionine or intravenous N-aectylcystone which may have a beneficial effect up coal least 48 hours after the overdose. may be required. General supportive measures most be available. Liver function tests should be performed at 14 hour intervals for at least 96 hours post-ingestion if the plasma paracetamol concentration indicates a potential for hepatotoxicity. Renal and cardiac function should be monitored and supportive,aceatmen1 should be directed at maintaining fluid and electrolyte balance and correc t nig hypo. itlycaernia. Haemodialysis and haeihoperfusion have been used with some success but peritoneal dialysis is met Incline
Drug Interaction:
the an: ire:mid:int effect of warta !I rid other coumarins may be e77411e VrorsIlljed minter daily use 01 paracetamol with increased. tisk of hired. ..aceaSlonal doses have no significant el rect.
Human and an mat studies have not osk to pregnancy or embryofoetal devetopment. Human studies have not identified any risk In lactation or the theasl-led offspring. Paracetamol crosses the placental barrier and is excreted in breast milk
Precaution & Warnings:    , s.    • .    •
Care is advised in the administration of paracetamol to patients with severe renal or severe hepatic impairment. The hazard of overdose is g tea ter In those with non-cirrhotic alcoholic liver disease. Patients who are taking other potentially hepatotoxic drugs are at increased risk of paracetamol-induced hepatoluxicity
Package & Storage:
Tablets, Strips of 10 tablets in packs of 2 strips. Store below 30 C
Syrup: Bottle of 125ml
Suppository: Box of 5 suppositories.
Storage: See outer pack.
Instruction to Patient:
On not exceed the stated dose.
Do not to take other paracetamol-containing products concurrently.
If symptoms persist consult your doctor.
If you have been diagnosed With liner or kidney impairment seek medical advice before taking this medication
KEEP ALL MEDICAMENTS OUT OF THE REACH OF CHILDREN
For tablets & Syrup: Manufactured by GlaxoSmithKline SA.E.- El Salam city-Cairo- Egypt.
For Suppositories: Manufactured by SmithKline Beecham - Elharam-Giza for GlaxoSmithKline SAE. - Egypt
Abimol is a trade mark of GlaxoSmithKlinc SA.E    SBCOCIaxoSmithKline

الاثنين، 9 يناير 2012

PONSTON* FORTE



(Active Ingre tent (metenamic acid For the relief pain and -nflammation
Composition: Film coated tablet contains 500 mg mefenamic aces Action: Mefenarnic acid is an analgesic with anti-intlammator properties and demonstrable anttyretrc effect It has also been shown to inhibit Prostaglandin activity. Indications: • Moderate pain. such as headache toothache. • Menstrual disorders (Menstrual pain. etc.) - Painful swelling or inflammation following injury or s imery. • Irritative conditions in degenerative joMts. • Spinal conditions. • Joint inflammations - None-articular rheenatism Contraindication:

This medication should not be used tn

: • Suspected impairment of hematopoiesis (blood foroationl. - Patients with gastrointestinal complaints (Streit as i;hronic diarrhoea) or a history astric or auodenal ulcers Cr This medication may only be used after careful conseteration of the risk/benefit ration - - Hypersensitivity to menfenarnic acid. intestinal inflammation (ulcerative colitis Crohn's disease). - Patients with eOirePsY-- Children less than 14 years of age. Special monitoring by the physician is required in - Patients who suffer from asthma, chronic obstuctee pulmonary disease (COPDI. tnt, fever or chronic swelling of the nasal mucosa (nasal polypi), since they are sueptible to hypersensitivity reactieroi (asthma attack, nettle rash. allergy-related oedema). - Patients who ha e have overreacted to to anti-Mean- matory drugs or pain reliefers, for e, ample. asthms attack, skin reactions or acute Miners. Administration in these ases should only be made when oertain precautions have been taken (emergency preparationS). • Patients with hepatic or renal impairment. • Patients with hypertension ancitcr cardiac decompc ieation. • elderly patients. Use During Pregnancy and Lactation: Ponstan Forte my not be used in the last trimester :if prgnancy, Ponsta, Forte should not be used in the first and second trimester of pregnancy and during lactation unless careful consideration has been given to the risk/benelit ration. Adverse events: Gastrointestinal complaints occer frequently, such as stomachache. nausea inild diarrhoea and slight gastrointestinal bleeding. which may result in anaemia in isolated cases.
111111111
The following may occur occasionally: - Gastrointestinal ulcers, sometimes with bleeding perforation. - Serious diarrhoea. In such cases. treatment with PONSTAN FORTE must be withdrawn. In rare cases, the following may be anticipated; - Central nervous disturbance., such as headache, blurred vision, fatigue, depression and di - Hypersensitivity reactions sec's as skin rash, allergic oedema. brochospasm end hypotension • Reduced excetion of sodium and water. • Impairment of hepatic furction The following has been observed in isolated cases: Impairment of hernatopoiesis. This impairment can affect all elements of the blood g in increased susceptibility to intection (for example with fever, sore throat). bleeding (epistaids. bleeding., skin without preceding injury) and signs of anaemia (marked apathy and pallor). In such cases, therapy ash PONSTAN FORTE must be discontinued immediately: - Increased excretion of lipids in stools and inflammation of the pancreas - Impaired renal function and kidney failure. Note: Used as directed, PONSTON FORTE may affect mental alertness, thus the capability of opei eing machinery. including motor venicles, is impaired. This applies especially when alcohol is consumed Interactions with other drugs: The of boad anticoagulants may be potentiated in concurrent treatment with PONSTON FORTE (danger of bleeding) No,nveerigations have been performed on the interaction of mefenarnic ace: with other active substances of known interactive potential (antihyperensive subsances, antidiabetics. digoxin, phenynin, lithium salts, e  Dosage and Administration: The recommended dose of mefenamic acid is 750- 1500 mg daily in general. adolescents from 14 years and adults take I tablet of PONSTON FORTE 2 to 3 times daily. Routttancl.Quration of Aslolifthileation The tablet should be swallowed whole with sufficient fluid during or after a meal. For longer periods cr administration, blood count should be controlled prior to and during thew-, The physician must decide or the duration of treatment. • NOTES - The medication should not be taken after the expiry date printed on the package. • If severe diarrhoea occurs, traatment with mefenamic acid must be withdrawn. - Kide.ey function must be monitored whett concurrently administered with a diuretic. THIS IS A MEDICAMENT: - Medicament is a product eit. tt affects your health, and its consumption contrary to instruction is dangerous for you • Follow strictly the doctors preeciiption, the method of use ard the instruction of the Orating:1st whc sold the medicament. - The doctor and the pharmacist are experts in medicine, its benefits and risks. • Do not by yourself interrupt tee period oi treatment prescribed. • Do not repeat the same prescription without consulting your doctor. BPToaliscbtkeearsgptoianrcegk of 20 lm d at temperature • 15°C - 30T). :s Fi coated tablets. Keep medicament out of the reach of children_
• ,sovoull, V9C.30 • .00.111
4
Manufactured by Pfizer Egypt S.A.E. Cairo A.R.E Under Authority of Pfizer INC., U.S.A

فوليك

حمض فوليك ميباكو
دواعى الاستعمال
مكمل غذائى

الجرعة
الجرعة الاولية :3-4 اقراص يوميا لمدة ستة ايام
الجرعة التكميلية :1-2 قرص يوميا تبعا لحالة

جينوزول

دواعى الاستعمال
التهابات المهبل الناشئة عن الاصابةبالفطريات مثل الكنديدا
اصابة المهبل بالفطريات والبكتيريا موجبة الجرام فى نفس الوقت
زيادة الافرازات المهبلية نتيجة الاصابة بالفطريات والبكتيريا

الجرعة
جينوزول:200 توضع كبسولة للمهبل عند النوم لمدة ستةايام متتالية
جينوزول :400توضع كبسولة بالمهبل عند النوم لمدة 3 ايام متتالية

جى ار 6

دواعى الاستعمال
مكمل غذائى

الجرعة
كبسولة واحدة يوميا